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Background: LAPTM4B is a member of the lysosome-associated transmembrane protein superfamily that is
differentially expressed in normal human tissues and upregulated in various types of carcinomas. These proteins are
thought to be involved in the regulation of cell proliferation and survival. The objective of this study was to
investigate the expression of bovine LAPTM4B during ovarian follicular development and in various bovine tissues.
Methods and results: Northern blot analysis revealed a 1.8 kb transcript, with highly variable steady state levels
among tissues. RT-PCR analysis showed that LAPTM4B mRNA transcripts were low in granulosa cells of small antral
follicles, increased in large dominant follicles, and decreased in ovulatory follicles following injection of human chorionic
gonadotropin (hCG; P < 0.003). Ovulatory follicles collected at various times after hCG injection revealed a significant
reduction of LAPTM4B mRNA starting at 18 h post-hCG (P < 0.029). Immunobloting analysis using antibodies generated
against bovine LAPTM4B recognized proteins of 26.3 and 31.5 kDa in granulosa cells of developing follicles and corpus
luteum. Further analyses of affinity-purified His-tag LAPTM4B overexpressed in HEK cells showed that the 31.5 kDa
protein represented the ubiquinated isoform of the 26.3 kDa native protein. The 26.3 kDa protein was differentially
expressed showing highest amounts in dominant follicles and lowest amounts in ovulatory follicles 24 h post-hCG.
Immunohistochemical analyses of LAPTM4B showed marked heterogeneity of labeling signal among tissues, with
LAPTM4B mainly localized to perinuclear vesicles, in keeping with its putative lysosomal membrane localization.
Conclusion: This study reports for the first time that bovine LAPTM4B in granulosa cells is present in both
unubiquinated and ubiquinated forms, and is differentially expressed in developing ovarian follicles, suggesting a
possible role in terminal follicular growth.
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The lysosome-associated protein transmembrane 4 beta
(LAPTM4B) belongs to the LAPTM gene family along
with LAPTM4A and LAPTM5. These proteins are classi-
fied according to the number of their transmembrane do-
mains [1,2] and are thought to be involved in the
regulation of cell proliferation and survival [3,4]. The
members of the LAPTM family share similarities to* Correspondence: k.ndiaye@umontreal.ca
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unless otherwise stated.lysosomal proteins since they are membrane proteins that
contain multiple tyrosine residues. These tyrosine-based
motifs function as addressing signals, targeting the pro-
teins toward lysosomes or late endosomes [3,5-7]. Specif-
ically, LAPTM4B was localized to lysosomes as well as to
the plasma membrane and internal organelles such as the
Golgi apparatus and endosomes [8]. LAPTM4B mRNA
was originally reported to be overexpressed in human he-
patocellular carcinoma [9] and widely expressed in other
normal human tissues, including total human ovarian ex-
tract [10]. Furthermore, its mRNA level was increased in
various types of carcinomas including breast, ovarian,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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basis, LAPTM4B promotes autophagy, a cell survival
mechanism mediated by lysosomes that renders tumor
cells resistant to metabolic and genotoxic stress, which
promotes a faster tumor growth rate [15]. Moreover,
knockdown of LAPTM4B mRNA using siRNA resulted in
increased sensitivity of tumor cells to anthracyclines, an
intercaling agent and a free radical inducer. Further ana-
lyses indicated that LAPTM4B overexpression resulted in
specific sequestration of anthracycline and delayed the
entry of anthracycline into the nucleus [15].
LAPTM4B has been studied mainly in human and
specifically in regard to its association with various car-
cinomas, as referenced above. In the present study, we
investigated the expression, localization, and regulation
of the LAPTM4B mRNA and protein in the bovine spe-
cies specifically during the final stages of ovarian follicu-
lar development. In a preliminary expression study, we
observed that LAPTM4B mRNA was strongly expressed
in granulosa cells of dominant or preovulatory follicles.
We also extended the analysis to other bovine tissues to
allow for comparisons since no data is available in the
bovine species.
The cyclic ovarian activity results in profound modifica-
tions that require spatio-temporal coordination of prolifer-
ation, apoptosis and differentiation of various cell types
within the follicles resulting from changes in gene expres-
sion. The growth of antral follicles is mainly under the in-
fluence of the follicle-stimulating hormone (FSH) [16].
During follicular selection and dominance, granulosa cells
acquire luteinizing hormone receptors (LHr) that allows
the transfer of follicle dependency from FSH to LH and
the increase in synthesis of oestradiol-17β [17,18]. The
preovulatory surge of LH from the anterior pituitary gland
results in ovulation and the release of the oocyte, and the
remaining granulosa and theca cells of the follicle wall dif-
ferentiate into luteal cells to form the corpus luteum and
produce progesterone [19]. Granulosa cells thus play a
critical role in reproductive functions as they contribute to
steroid hormone synthesis [20], oocyte maturation [21],
and corpus luteum formation after ovulation [22]. The
transcription of genes in granulosa cells that control the
growth of a bovine dominant or preovulatory follicle is
rapidly downregulated or silenced as a result of LH-
mediated increases in intracellular signaling [23]. Con-
versely, LH upregulates or induces the expression of genes
involved in ovulation and luteinization [24-26]. These
studies demonstrate the critical importance of gene
expression and regulation studies during the final stages of
follicular development and ovulation. In this study, we
report the differential regulation and localization of
LAPTM4B in granulosa cells during the periovulatory
period as well as in other bovine tissues that lead to a bet-
ter understanding of its physiological function.Methods
Experimental animal models
The regulation of LAPTM4B expression during follicular
development and ovulation was studied using in vivo
models as previously characterized [23]. Estrous cycles of
normal cycling crossbred heifers were synchronized with
one injection of PGF2α (25 mg, im; Lutalyse, Upjohn,
Kalamazoo, MI) given in the presence of a corpus luteum,
and ovarian follicular development was monitored by daily
transrectal ultrasonography. Following estrous synchro-
nization, heifers were randomly assigned to the dominant
follicle group (DF, n = 4), or the ovulatory hCG-induced
follicle group (OF, n = 4). In the DF group, the ovary bear-
ing the DF on the morning of day 5 of the estrous cycle
(day 0 = day of estrus) was obtained by ovariectomy (via
colpotomy). The DF was defined as > 8 mm in diameter
and growing while subordinate follicles were either static
or regressing. The OF were obtained following an injec-
tion of 25 mg of PGF2α (Lutalyse) on day 7 to induce
luteolysis, thereby promoting the development of the DF
of the first follicular wave into a preovulatory follicle. An
ovulatory dose of hCG (3000 IU, iv; APL, Ayerst Lab,
Montréal, QC) was injected 36 h after the induction of
luteolysis, and the ovary bearing the hCG-induced OF was
collected by ovariectomy at 0, 6, 12, 18, and 24 h after
hCG injection (n = 2–4 cows/time point). Immediately fol-
lowing ovariectomy, follicles were dissected into prepara-
tions of follicular wall (theca interna with attached
granulosa cells) [27] or further dissected into separate iso-
lates of granulosa cells [23], and stored at −70°C. Add-
itionally, GC were collected from 2 to 4 mm small follicles
(SF) obtained from slaughterhouse ovaries, and a total of
three pools of 20 SF was prepared. Concentrations of
progesterone (P4), and estradiol-17β (E2), and their ratio
(P4/E2) were validated by radioimmunoassay of follicular
fluid as previously described [23]. Corpora lutea (CL) at
day 5 of the estrous cycle were obtained by ovariectomy
and were dissected from the ovarian stroma, frozen in
liquid nitrogen, and then stored at −70°C. The Animal
Ethics Committee of the Faculty of Veterinary Medicine
of the University of Montreal approved all animal
procedures.
Cloning of bovine LAPTM4B
The LAPTM4B cDNA was cloned from a bovine cDNA
library prepared with polyA+ mRNA isolated from GC
of dominant follicles at day 5 of the estrous cycle as de-
scribed above. The cDNA library was constructed in
lambda Zap Express vector (Stratagene, La Jolla, CA) by
unidirectional cloning of cDNAs as previously described
[28]. Following in vivo excision of pBluescript phagemids
containing the cloned cDNA insert with the Ex-Assist/
XLOLR system (Stratagene), single bacterial colonies
were randomly picked and their phagemid content were
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LAPTM4B cDNA was entirely characterized by sequen-
cing on an ABI Prism 310 (Applied BioSystem).
The 5′-end of the bovine LAPTM4B was verified by
screening a genomic DNA library to eventually yield all the
5′-untranslated region and promoter sequences. The gen-
omic DNA library was prepared in Lambda phages (BD
Biosciences Clontech) and 1×107 pfu was screened using
the bovine LAPTM4B cDNA (GenBank NM_205802) as a
P32-radiolabelled probe. Hybridized clones were analyzed
by PCR using specific probes designed in the 5′-UTR of
the LAPTM4B cDNA (forward: GCGAGCTCTTCGCGG
GGAGAG; reverse: CAAGTACCAGACGCCGAGCAG).
A second round of screening was performed to isolate a
positive clone. Recombinant DNA was purified as de-
scribed [29], cloned into the pDrive vector (Qiagen Clon-
ing kit) following BamH1 digestion, and characterized by
sequencing.
mRNA expression analysis
RNA was isolated from various bovine tissues obtained
from slaughterhouse by extraction in lysis buffer (4 M
guanidium isothiocyanate, 0.5% Na-N-laurylsarcosine,
25 mM Na-citrate, pH 7), sedimentation, and centrifuga-
tion on a cesium chloride cushion as previously described
[28]. The concentration of total RNA was quantified by
measurement of optical density at 260 nm, and quality
was evaluated by visualizing the 28S and 18S ribosomal
bands following electrophoretic separation on 0.66 M for-
maldehyde denaturing 1% agarose gel with ethidium
bromide [29]. Expression of LAPTM4B mRNA in various
tissues was compared by Northern analysis. Total RNA
(20 μg/tissue) was size-fractionned on a 0.66 M formalde-
hyde 1% agarose gel, transfered by capillarity onto a nylon
membrane (Hybond-N; GE Healthcare Life Sciences), and
UV-treated (150 mJ) as previously described [28]. The
amount of ribosomal RNA (18S) was estimated after
methylene blue staining and the image was digitized
(FotoDyne Inc., Hartland, WI) and analyzed using the
NIH Image software. The bovine LAPTM4B cDNA was
used to generate a radioactive probe incorporating [α32P]-
dCTP (NEN Life Sciences, Boston, MA) that was subse-
quently used to hybridize Northern blots as described
[28]. The film images were digitized and the intensity of
bands expressed as ratios of 18S ribosomal RNA.
Expression and regulation of LAPTM4B mRNA during
follicular development and following hCG injection was
analyzed by semi-quantitative RT-PCR. Total RNA was
extracted from bovine GC collected from follicles at dif-
ferent developmental stages (SF, DF, OF) and CL, and
from follicular wall (granulosa and theca cells) collected
at 0, 6, 12, 18, and 24 hours after an injection of hCG.
The sample at 0 hour was represented by day 7 domin-
ant follicle (DF). Specific LAPTM4B PCR primers wereused and the number of cycles was limited and opti-
mized for analysis of LAPTM4B mRNA expression. PCR
reaction products were separated on a 2% TAE-agarose
gel with ethidium bromide, visualized by UV light, digi-
tized and analyzed by densitometry using ImageQuant
software (GE Healthcare Life Sciences). GAPDH was
used as a control gene, and specific signals of LAPTM4B
were normalized with corresponding GAPDH signals.
Production of polyclonal anti-bovine LAPTM4B antibodies
A fragment corresponding to amino acids Lys169 to
Ala225 (LAPTM4B; Molecular weight = 7.5 kDa) located
at the carboxy-terminal end of the bovine LAPTM4B
was used to generate a glutathione S-transferase fusion
protein (GST Gene Fusion System; GE Healthcare Life
Sciences) to produce specific polyclonal antibodies. To
increase the molecular weight of LAPTM4B recombin-
ant protein fragment and thus facilitate down-stream
purification procedures, a DNA construct that included
a tandem repeat of Lys169 to Ala225 (LA)2-LAPTM4B
fragments cloned at the carboxy-terminal end of the
GST was generated. A set of forward (5′-AAGGGT
TACTTGATTAGCTGTGTTTGG-3′) and reverse (5′-
GGCAGACACGTACGGGGGC-3′) primers that in-
corporated BamHI (forward primer) and EcoRI (reverse
primer) restriction sites were designed from the LAPTM4B
cDNA to generate the first LAPTM4B fragment. The
same set of primers that incorporated an EcoRI (forward
primer) and SalI (reverse primer) were used to generate
the second LAPTM4B fragment. The LAPTM4B frag-
ments were amplified by PCR using the Expand High
Fidelity polymerase (Roche Molecular Biochemicals) ac-
cording to the manufacturer’s protocol. The fragments
were isolated after electrophoresis, digested with either
BamHI and EcoRI (for the first fragment), or EcoRI and
SalI (for the second fragment). The first fragment was
subcloned into the pGEX-2 T vector (GE Healthcare Life
Sciences) in frame with the GST coding region, as de-
scribed previously [28]. The second fragment was then
subcloned down-stream of the GST-LAPTM4B first
fragment, and the resulting plasmid sequenced to con-
firm its integrity. Protease-deficient E. coli BL-21 (GE
Healthcare Life Sciences) were transformed with the
(LA)2-LAPTM4B/pGEX-2 T construct, and expression of
recombinant (LA)2-LAPTM4B/GST fusion protein was
induced with 0.1 mM isopropyl-1-thio-β-D-galactopyra-
noside (IPTG) for 6 hours. Proteins from bacterial ex-
tracts were obtained after sonication as previously
described [28]. The (LA)2-LAPTM4B/GST-fusion protein
was purified by affinity on glutathione-Sepharose beads
(GE Healthcare Life Sciences), and digested with thrombin
(10units/1 mg of fusion protein) to release the tandem
(LA)2-LAPTM4B fragment. Proteins were resolved by one-
dimensional SDS-PAGE, transferred onto nitrocellulose
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ences), and stained with Ponceau S red. The tandem (LA)2-
LAPTM4B band (MW=15.3 kDa) was cut and used to
immunize a rabbit as previously described [28]. Preceeding
immunization, the identity of the purified (LA)2-LAPTM4B
fragment was verified by liquid chromatography-tandem
mass spectrometry (Eastern Quebec Proteomics Center,
Laval University, Quebec, Canada). Polyclonal antibodies
against bovine LAPTM4B were validated by immunoblot-
ting using the GST-affinity purified recombinant (LA)2-
LAPTM4B.
Cell extracts and immunoblotting analysis
Granulosa cells and CL were obtained as described
above. They were homogenized in M-PER buffer (Pierce,
Rockford, IL, USA) supplemented with complete prote-
ase inhibitors (Roche Diagnostics, Laval, QC, Canada) as
described by the manufacter’s protocol, and centrifuged
at 16,000 × g for 10 min at 4°C. The recovered super-
natant was stored at −70°C until electrophoretic analyses
were performed. Protein concentrations were deter-
mined according to Bradford method [30] (Bio-Rad Pro-
tein Assay, Bio-Rad Lab, Mississauga, ON, Canada).
Immunoblotting was performed as described previously
[28]. Samples (50 μg of proteins) were resolved by
one-dimensional denaturing Novex Tris-glycine gels
(Invitrogen, Burlington, ON, Canada) and electrophoretic-
ally transferred to polyvinylidene difluoride membranes
(PVDF; GE Healthcare Life Sciences). Membranes were
incubated with the polyclonal anti-bovine LAPTM4B anti-
body (1:2000), and immunoreactive proteins were visual-
ized by incubation with horseradish peroxidase-linked
donkey anti-rabbit secondary antibody (1:20 000 dilution)
and the enhanced chemiluminescence system, ECL plus
(GE Healthcare Life Sciences) according to the manufac-
turer’s protocol followed by revelation using the Chemi-
Doc XRS+ system (Bio-Rad).
Overexpression of bovine LAPTM4B in mammalian cells
To confirm the detection of the two forms of LAPTM4B
protein with our antibodies, overexpression experiments
in mammalian cells were performed. The LAPTM4B open
reading frame was amplified by PCR using the Expand
High Fidelity polymerase (Roche Molecular Biochemicals)
with specific LAPTM4B primers. The PCR fragment
was purified and cloned into pQE-TriSystem His-Strep2
(Qiagen). The final construct pQE2-LAPTM4B was used
to transfect HEK cells using the CalPhos mammalian
transfection kit (Clontech Laboratories, Inc.) according to
the manufacturer’s protocol. Seventy-two hours post-
transfection, cells were harvested and protein extraction
as well as immunoblotting was performed as described
above using the anti-LAPTM4B antibody generated from
the present study and a commercial anti-LAPTM4Bantibody (Abcam Inc.; cat. # ab82810, at a concentration
of 1 μg/ml). To verify for ubiquitination of the LAPTM4B
protein, immunoblotting was also performed using a
monoclonal anti-ubiquitin antibody (Sigma U0508 at
1:2,500 dilution). Immunoreactive proteins were visualized
by incubation with horseradish peroxidase-linked sheep
anti-mouse secondary antibody (1:20 000 dilution) and
the enhanced chemiluminescence system, ECL plus
(GE Healthcare Life Sciences) according to the manu-
facturer’s protocol followed by revelation using the
ChemiDoc XRS+ system (Bio-Rad).
Immunohistochemistry
Immunohistochemistry was performed on PBS buffered
formaline-fixed follicles and CL that were generated as
described above, as well as on bovine tissues obtained
from slaughterhouse. Paraffin-embedded tissues were
cut at 4 μm thickness, mounted on SuperfrostPlus slides
(Fischer Scientific, QC), deparaffined and rehydrated.
Tissue sections were heat-treated as previously described
[28], and were incubated for 14 h at 4°C with our anti-
LAPTM4B antibody at a dilution of 1:500 in Tris-
buffered saline (TBS; 150 mM NaCl, 0.1 M Tris pH 7.5)
containing 1% bovine serum albumin, and 1% fat-free
skim milk. Control tissue sections were incubated simi-
larly with preimmune serum. The primary antibody and
LAPTM4B antigen complexes were detected by incuba-
tion with a monoclonal anti-rabbit IgG conjugated with
alkaline phosphatase (Sigma Chemicals) at a dilution of
1:200 for 2 h at room temperature, followed by several
washes in TBS, and incubation with the NBT/BCIP alka-
line phosphatase substrate (Roche Diagnostics). Sections
were mounted in 5% gelatin, 27% glycerol, and 0.1% so-
dium azide. Photographs were taken under bright field
illumination using a Nikon Eclipse E800 microscope
equipped with a digital camera (Nikon DXM 1200).
Digital images were processed by the Photoshop soft-
ware (Adobe Systems Inc., San Jose, CA) and assembled
by the Illustrator software (Adobe Systems Inc.).
Statistical analysis
Amounts of LAPTM4B mRNA were normalized with
those of the control gene GAPDH. Homogeneity of
variance between groups was verified by O’Brien and
Brown-Forsythe tests. Corrected values of gene specific
mRNA levels were compared between follicular or CL
groups by one-way ANOVA. When ANOVA indicated a
significant difference (P < 0.05), the Tukey-Kramer test
was used for multiple comparison of individual means
among SF, DF, OF and CL, whereas the Dunnett test (P <
0.05) was used to compare different time points after hCG
with 0 h as control. Data were presented as least-square
means ± SEM. Statistical analyses were performed using
JMP software (SAS Institute, Inc.).
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Isolation and expression analysis of bovine LAPTM4B
mRNA
The of LAPTM4B cDNA was isolated from a lambda
phage cDNA library constructed from bovine GC
collected from dominant follicles at day 5 of the estrous
cycle, and characterized by sequencing [GenBank:
AF276819]. LAPTM4B expression was analyzed at the
mRNA level via Northern blot analysis using several bo-
vine tissues. A single transcript of LAPTM4B was de-
tected at 1.8 kb, and the intensity of the signal was
highly variable among tissues (Figure 1). The LAPTM4B
steady state mRNA levels were strongest in fetal ovary,
testis, adrenal gland, liver and uterus, moderately
expressed in other tissues, and the weakest expression
was observed in the spleen (Figure 1). The expression
pattern of LAPTM4B during follicular development and
ovulation was investigated by semi-quantitative RT-PCR
using mRNA samples derived from GC at different fol-
licular developmental stages and CL at D5 of the estrous
cycle. LAPTM4B mRNA was differentially expressed
with the strongest expression in DF compared to SF, OF
and CL (P < 0.003; Figure 2A). Levels of LAPTM4B tran-
script increased by nearly 2-fold in GC of DF compared
to SF, and declined by 2.4-fold in OF as compared to








































































Figure 1 Analysis of bovine LAPTM4B mRNA expression in bovine tis
tissues and samples (20 μg/well) were analyzed by Northern blot as describ
transcript corresponding to LAPTM4B mRNA was detected and showed a v
steady state levels of bLAPTM4B mRNA expression corrected using 18S rRNin GC 24 h following its injection, we studied its expres-
sion in follicular walls obtained from ovulatory follicles
that were isolated at different time points between 0 and
24 hours after hCG treatment (Figure 2B). A significant
decline in LAPTM4B mRNA expression was observed at
18 hours following hCG when compared to 0 h (P <
0.029) and reached the lowest level at 24 hours.
Production of an anti-bovine LAPTM4B antibody and
immunoblotting analysis
The recombinant bovine LAPTM4B fragment corre-
sponding to Lys169- Ala226, with a theoritical MW of
7.5 kDa, was produced in tandem (LA)2-LAPTM4B and
released from GST by thrombin digestion. The (LA)2-
LAPTM4B peptide fragment migrated at 15.3 kDa on a
denaturing SDS-PAGE gel and was sequenced by mass
spectrometry, which confirmed its identity. The (LA)2-
LAPTM4B was used as immunizing antigen to generate
anti-bovine LAPTM4B polyclonal antibodies. Immuno-
blotting analyses showed that the antibody preparation
recognized the affinity-purified and thrombin-cleaved
(LA)2-LAPTM4B fragment that migrated at 15.3 kDa
(Figure 3A). The antibody recognized the native
LAPTM4B migrating at a MW of 26.3 kDa (Figure 3B)
in total protein extracts of GC and CL, which corre-
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Figure 2 Regulation of LAPTM4B mRNA expression during follicular development using semi-quantitative RT-PCR. RNA samples were
collected from bovine GC of 2–4 mm follicles (SF), dominant follicles at Day 5 of the estrous cycle (DF), ovulatory follicles 24 h after injection of
hCG (OF), and CL at Day 5 of the estrous cycle (panel A), and from follicular walls (granulosa cells and theca interna) at different time-point: 0, 6,
12, 18 and 24 hours post-hCG (panel B); 0 h corresponds to day 7 dominant follicle. GAPDH was used as control gene, and showed no significant
difference in mRNA expression levels among samples. Gene-specific signals were normalized with corresponding GAPDH signals for each sample.
A. Expression of LAPTM4B displayed a 2-fold and 2.4-fold greater expression amounts in DF than in SF and in OF, respectively (ANOVA: P < 0.003).
B. LAPTM4B expression was significantly downregulated starting at 18 hours following hCG injection compared to 0 hour (ANOVA: P < 0.029).
Different letters denote samples that are significantly different (P < 0.05) when Tukey-Kramer multiple comparison test (panel A) or Dunett test
(panel B) were performed. Data are presented as least-square means ± SEM, and the number of independent samples per group is indicated
in parenthesis.
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detected (Figure 3B). Comparison of the 26.3 kDa
LAPTM4B protein expression showed greatest amounts
in GC of DF whereas moderate expression was observed
in CL, and significantly weaker expression was observed
in OF and SF as compared to DF (P < 0.03; Figure 3C).
The 31.5 kDa form showed no statistically significant
variation among the different follicular stages and CLalthough its concentration was 2.6-fold weaker in OF
than in DF. Overexpression experiments of the full-
length LAPTM4B cDNA in HEK cells confirmed that
two protein forms were produced from the single
cDNA. These two forms were recognized at 26.3 and
31.5 kDa by the anti-LAPTM4B antibodies generated
in this study (Figure 4A) and by the one acquired com-
mercially (Figure 4B). The His-tag LAPTM4B protein

































































Figure 3 Comparison of bovine LAPTM4B protein expression. Total protein extracts (50 μg/well) from granulosa cells of 2–4 mm small
follicles (SF), dominant follicles at Day 5 of the estrous cycle (DF), ovulatory follicles 24 h after hCG injection (OF), CL at Day 5 and the
recombinant LAPTM4B fragment were size-fractionned on a 15% denaturing SDS-PAGE gel and immunoblotted using the anti-bovine (LA)2-
LAPTM4B polyclonal antibody as described under Materials and Methods. A. The recombinant tandem fragment (LA)2-LAPTM4B was specifically
recognized at 15.3 kDa. B. The results for the protein extracts of representative follicles and CL are shown. The native bovine LAPTM4B showed
two forms migrating at 26.3 kDa and at 31.5 kDa. A stronger signal of the 26.3 kDa protein was observed in DF, and the weakest signal was
observed in OF. Expression of the 31.5 kDa form was not statistically different among samples. C. The relative intensities of the 26.3 kDa and
31.5 kDa bands were quantified by densitometry and are represented. The results are presented as means ± SEM of two independent samples per
group, and bars with different letters indicate significantly different values (P < 0.05).
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by immunoblotting using anti-bovine ubiquitin antibodies
that detected a single protein band at 31.5 kDa indicating
ubiquitination of LAPTM4B (Figure 4C).
Immunolocalization of LAPTM4B
Immunohistochemical analyses provided evidence that
LAPTM4B expression in bovine tissues is variable and spe-
cific given the pattern of expression observed even among
similar cell types within a tissue. In GC, a perinuclearpattern of immunostaining was observed in all cells
(Figure 5A). Dominant follicles obtained at day 5 showed a
labeling signal in GC that was stronger compared to GC
from follicles obtained 24 h following hCG injection
(Figure 5B). Theca cells were also stained but the staining
was weaker compared to GC (Figure 5A-B). For the CL,
immunolabeling was variable among luteal cell types and
within each cell type (Figure 5C,D). For instance, large
luteal cells presented a weaker or no signal as compared





B) A) C) 
Lane 1 = His-tag LAPTM4B transfected cells
Lane 2 = Non-transfected cells
1 2 1 2 1 2 kDa kDa kDa
Figure 4 Overexpression analysis of LAPTM4B in HEK cells. LAPTM4B was cloned into the his-tag pQE2 vector and used to transfect HEK cells.
Proteins were extracted and subjected to immunoblotting using the anti-bovine (LA)2-LAPTM4B polyclonal antibody (panel A) or a commercially
available anti-LAPTM4B antibody (panel B). Two proteins of 26.3 and 31.5 kDa were observed with both antibodies. His-tag LAPTM4B proteins
produced by HEK cells were purified by affinity chromatography and subjected to immunoblotting using a bovine ubiquitin antibody that only
recognized the 31.5 kDa LAPTM4B form (panel C).
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LAPTM4B mRNA expression in different tissues was vari-
able among the tissues analyzed (Figure 1), we extended
the immunohistochemical observations to other female
and male reproductive tissues. Epithelial and glandular
endometrial cells showed a variable pattern of immuno-
staining even among adjacent cells (Figure 5E,F). Interest-
ingly, endometrial glandular cells that were closer to the
uterine lumen showed a stronger signal compared to the
endometrial cells located deeper in the gland (not shown).
In oviductal epithelial cells, heterogeneity of staining for
LAPTM4B was also noticeable, with weak to strong signals
associated with variable localization, being either peri-
nuclear or at the baso-lateral or at apical side of cells
(Figure 5G). In the testis, the intensity of immunostaining
was variable between seminiferous tubules and was associ-
ated with Sertoli cells (Figure 5H). Epithelial cells of the
seminal gland showed a variable expression pattern associ-
ated with a strong to weak signal even for adjacent groups
of cells (Figure 5 I,J). Epithelial cells lining the epidydimis
tail ducts showed immunolabeling signal from intense to
weak that varied between ducts (Figure 5K). In the granu-
lar layer of the cerebellum, granular cells were weakly
stained whereas strong perinuclear labeling was associated
to Golgi cells. Purkinje cells were not labeled (Figure 5L).
In the adenohypophysis, strong immunolabeling was asso-
ciated to the folliculo-stellate cells (Figure 5M,N). In the
liver, hepatocytes located near the centrolobular vein
demonstrated a stronger perinuclear signal than hepato-
cytes that were located eccentric to the centrolobular vein
(Figure 5O,P).
Discussion
This study is the first to report that LAPTM4B expres-
sion is differentially regulated at the mRNA and protein
levels in granulosa cells at critical stages of follicular de-
velopment, being stronger at the time of dominancethan at recruitment (2–4 mm diameter), at the time of
ovulation and in luteal cells. LAPTM4B differential ex-
pression extends to different bovine tissues. Moreover,
immunohistochemical observations revealed that bovine
LAPTM4B expression was highly variable among tissues
and even among identical cell types of the same tissue.
The mRNA expression study of LAPTM4B in different
bovine tissues revealed a single transcript of 1.8 kb,
which corresponds well to the length of the cDNA char-
acterized by sequencing from the granulosa cells cDNA
library. Interestingly, two transcripts of 2.2 kb and 1.5 kb
were reported in human and were named LAPTM4B
variant 1 and variant 2, respectively [10,12,13,31]. The
size of the human LAPTM4B variant 2 (GenBank acces-
sion number: AF527412; [10]) corresponds to the bovine
LAPTM4B cDNA characterized in this study. By im-
munoblotting analysis of hepatocellular carcinoma and
normal liver tissue, it was shown that human LAPTM4B
was expressed as two isoforms that were translated from
alternative ATG codons [12]. The apparent molecular
weights of the isoforms were 35 and 24 kDa, corre-
sponding to predicted 317- and 226-amino acid proteins,
respectively. Expression of the 35-kDa isoform was
greater in highly metastatic cell lines originating from
liver, prostate, and pulmonary giant cell cancers than in
syngenic low metastatic cell lines [12]. Immunoblotting
analyses in the present study using antibodies raised
against bovine LAPTM4B showed the presence of two
proteins migrating at 26.3 kDa and 31.5 kDa, which
corroborates the molecular weight of the protein ob-
served in human [12]. However, contrary to the human
LAPTM4B cDNA, the cDNA of the bovine LAPTM4B
contains a single initiation codon of translation and the
size of the bovine cDNA characterized herein corresponds
to the size of the transcript estimated by Northern blot
(1.8 kb). To further characterize and verify the 5′-UTR re-































































Figure 5 Immunohistochemical localization of LAPTM4B in bovine
tissues. Sections of paraffin-embedded tissues were incubated with the
antibody directed against the recombinant bovine LAPTM4B (1: 500
dilution) and the complex was detected with a monoclonal anti-rabbit
antibody coupled to alkaline phosphatase and NBT/BCIP as substrate.
No counter staining was used. Bar = 0.1 mm if not otherwise stated.
A. Follicular wall of a day 5 dominant follicle; A antrum, G granulosa,
S stroma, T theca interna. B. Follicular wall of an ovulatory follicle 24 h
following hCG-injection. C. Corpus luteum at day 5 of the estrous cycle;
LC large luteal cells, SC small luteal cells. D. Higher magnification of the
corpus luteum section presented in C; V perinuclear vesicles. Bar =
0.05 mm. E, F. Endometrium; EE endometrial epithelial cells, EG endometrial
glandular cells, L lumen, S stroma, bar= 0.05 mm. G. Oviduct; OE
Oviductal epithelial cells, S stroma, L lumen. H. Prepupertal testis; ST
Seminiferous tubule, Le Leydig cells. I. Seminal vesicle; EC Epithelial cells,
L lumen, S stroma. J. Higher magnification of seminal vesicle
presented in J. K. Tail of epididymis; EC epithelial cells, S stroma, L
lumen. L. Cerebellum; GL granular layer, ML molecular layer, GrC
granular cells, GoC Golgi cells, PC Purkinje cells. M. Adenohypophysis;
FSC folliculo-stellate cells. N. Higher magnification of adenohypophysis
presented in M. O. Liver; CLV centrolobular vein. P. Higher magnification
of hepatocytes presented in L; Bar= 0.05 mm.
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quences. The sequencing results showed that there was a
single open reading frame coding for the 26.3 kDa form.
Following the synthesis of the 26.3 kDa bovine protein,
post-translational modifications may result in the 31.5 kDa
protein. The anti-bovine as well as commercially available
anti-human LAPTM4B antibodies recognized the two pro-
tein isoforms when bovine LAPTM4B cDNA was overex-
pressed in HEK cells. These results suggested a specific
binding to the 26.3 and 31.5 kDa proteins rather than a
cross reaction with a non-related protein. The affinity
purified His-tag LAPTM4B protein overexpressed in HEK
cells was analyzed by immunoblotting using anti-ubiquitin
antibodies and demonstrated that the 26.3 kDa protein
undergoes mono-ubiquitination thereby resulting in the
31.5 kDa isoform. The difference in molecular weight
between the estimated 26.3 and 31.5 kDa corresponds
well to the theoritical molecular weight of ubiquitin.
This result is also supported by the recent observation
that ubiquitination has a role in membrane sorting of
LAPTM4 proteins [8].
Comparison of mRNA steady state levels in follicles at
different developmental stages has shown that LAPTM4B
was expressed in GC of SF, reached strongest expression
in DF and declined in OF. Similarly, immunoblotting
analysis revealed a variable expression of the 26.3 kDa
LAPTM4B protein that paralled the mRNA results.
Amounts of LAPTM4B protein were low in SF, highest in
DF and lowest in OF. The comparison of LAPTM4B ex-
pression by immunohistochemistry provided further sup-
port that it is expressed in GC of DF, and this expression
is reduced in OF 24 h following hCG treatment. Immuno-
blotting analysis showed no significant variation in the
Ndiaye et al. Journal of Ovarian Research  (2015) 8:12 Page 10 of 11concentration of the 31.5 kDa protein, which could be
related to the stability and accumulation of the 31.5 kDa
isoform in lysosomes following ubiquitination of the
26.3 kDa protein. Thus, de novo synthesis of LAPTM4B
protein may be better reflected by the 26.3 kDa isoform,
which paralleled the variations observed at the mRNA
level.
The immunohistochemistry results suggest that bovine
LAPTM4B has a lysosomal localization as shown by the
perinuclear staining in different cell types. Located at its
carboxy terminal end, LAPTM4B contains a lysosomal tar-
geting motif and was also shown to co-immunoprecipitate
with ubiquitin ligase Nedd4 [3,8]. Ubiquitination of
LAPTM4B by Nedd4 may contributes to its targeting
towards late endosomes and lysosomes [8,32]. These ob-
servations correlate well with a lysosomal localization as
previously observed for human LAPTM4B [8] and for
LAPTM4A [4,33]. Interestingly, folliculo-stellate cells in
the adenohypophysis were strongly labeled and they are
known as scavengers with high lysosomal activity [34]. In
the ovarian follicle, granulosa and theca cells were labeled
almost uniformly probably reflecting a synchrony in cell
development necessary to insure active follicular develop-
ment. In contrast, heterogeneity of labeling was observed
in other tissues for similar and adjacent cell types. This
was particularly striking in tissues such as the epithelial
cells lining the oviduct, the uterus, the epididymis and the
seminal gland. In these tissues, some epithelial cells did
not stain while adjacent cells were strongly labeled. This
could reflect a different physiological state between these
epithelial cells within the tissue.
The results observed for the bovine LAPTM4B mRNA
and protein regulation, which is predominant in DF while
reduced in OF, suggest a potential role of LAPTM4B in the
growth of ovarian follicles. It was proposed that human
LAPTM4B promoted cell proliferation since it was over-
expressed in liver tumors [11], and was differentially
expressed with potential tumorigenic significance associated
with pituitary tumorigenesis [14]. Moreover, knockdown
and overexpression studies of LAPTM4B demonstrated its
capacity in binding and sequestring chemotherapeutic
agents towards lysosomes thereby inhibiting their action
and conferring chemotherapeutic resistance [15,35-37].
Comparatively, another member of the LAPTM super-
family, LAPTM4A, was involved in cellular detoxification
processes through transport of toxic substances in late
endosomes and toward lysosomes, thereby participating in
cell survival [4,33]. Thus, expression of LAPTM4B in
follicular and luteal cells could act as a survival factor
through sequestration and detoxification of metabolites
into lysosomes. Since granulosa cells of growing dominant
follicle are metabolically and steroidogenically very active,
LAPTM4B may confer protection against accumulation of
metabolic byproducts and induction of apoptosis.Competing interests
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